Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you live under a rock, you’ve heard about injectable GLP-1 agonist drugs like ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...

Recent studies have shed light on these medications’ benefits and potential risks. Ozempic’s common side effects include nausea, diarrhea, constipation, and acid reflux, which are generally mild ...

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Ozempic and other semaglutide medications have skyrocketed in popularity as weight-loss aids, with prescriptions surging by ...

The FDA approval is based on results from a trial investigating the effects of once-a-week Ozempic injections on major kidney ...

The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...